HONG KONG - Immuno-oncology company Ziopharm Oncology Inc. and cell therapy company Triarm Therapeutics Ltd. are set to establish a joint venture (JV), Eden Biocell Ltd., to develop and commercialize CAR T therapies targeting CD19 antigen in the greater China region and South Korea, with the use of a technology platform named Sleeping Beauty.